Achillion Pharmaceuticals Inc. (Nasdaq: ACHN) reported upbeat preclinical results for its Phase 2 pan-genotypic protease inhibitor ACH-1625 sending the stock price soaring $2.29 to close at $11.04.
Upbeat Preclinical Results For Achillion Pharmaceuticals
February 17, 2012 at 15:44 PM EST
